engleski

Memantine – pharmacoeconomic modelling in moderate to severe Alzheimer`s disease

In treating of moderate to severe Alzheimer patients, N-methyl D-aspartat antagonist memantine has demonstrated better results and correlations with decreased hospitalization rate, thus decreasing total health costs. Most of pharmacoeconomic studies for this disease consider societal perspective using cost effectiveness principle and QUALY parameters. This paper considers payer perspective (Croatian Department for Health Insurance) and takes into account direct cost of the disease as requested in Croatian guidelines for drugs reimbursement. Goal The aim of the paper was to assess direct cost of ilness with and without treatment with memantine, through a three year perspective. Methods Due to lack of (inaccurate) epidemiological dana, authors have undertaken further data search: the paper demonstrates cost variables taken from Croatian real life environment of treating Alzheimer patients acquired by delphi consensus method. Markov model was created for Croatian case to assess effect of the drug on hospitalization frequency and other direct treatment costs. Model stability was tested with Monte Carlo simulations. Results/Conclusion Results demonstrate memantine domination in terms of efficiency and cost reduction. It may be concluded that memantine reimbursement may bring cost saving not only to health budget of the payer, but also to other hospital related costs.

memantine – pharmacoeconomic modelling in moderate to severe Alzheimer`s disease

nije evidentirano